Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
Open accessThe DOI matches its Crossref record; 137 of the 138 references it cites were found in a registry or an index.
Abstract
Viral hepatitis, alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are the three major causes of chronic liver diseases, which account for approximately 2 million deaths per year worldwide. The current direct-acting antiviral drugs and vaccinations have effectively reduced and ameliorated viral hepatitis infection, but there are still no effective drug treatments for ALD, NAFLD and liver cancer due to the poor understanding of their pathogenesis. To better understand the pathogenesis, the fifth Chinese American Liver Society/Society of Chinese Bioscientists in America Hepatology Division Annual Symposium, which was held virtually on 21–22 October 2022, focused on the topics related to ALD, NAFLD and liver cancer. Here, we briefly highlight the presentations that focus on the current progress in basic and translational research in ALD, NAFLD and liver cancer. The roles of non-coding RNA, autophagy, extrahepatic signalling, macrophages, etc in liver diseases are deliberated, and the application of single-cell RNA sequencing in the study of liver disease is also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Fast-paced recent advances in single-cell-resolved technologies have allowed the scientific community to dissect the liver cellular landscape with unprecedented depth, particularly highlighting the previously overlooked intricate cellular crosstalk between the liver and immune cells [332–334].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [334]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Research works printed but not linked: 1
- Ma, 2022, Mitochondrial dynamics and stasis are critical for hepatocyte function and liver tumorigenesis, Hepatology, 76, S168
Cited by
(2025) · doi:10.1038/s41423-025-01313-7 · Cited by 97
Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis
Chen, L., Qiu, W., Sun, X., Gao, M., Zhao, Y., Li, M., Fan, Z., & Lv, G. (2023) · Gut · doi:10.1136/gutjnl-2023-330784 · Cited by 66
Wu, Y., Yan, Q., Yue, S.-Q., Pan, L., Yang, D., Tao, L.-S., Wei, Z., Fan, R., Qian, C., Han, M.-Q., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.92337 · Cited by 52
mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics
Yang, B., Liu, J., Yang, L., & Liu, X. (2025) · Cancer Innovation · doi:10.1002/cai2.70041 · Cited by 20
Guan, Y., Kim, Y. S., Wang, Y., Cho, Y. E., Xiang, X., Kim, S., Yao, T., Feng, D., Hwang, S., & Gao, B. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190635 · Cited by 14
Metadata
- Authors
- Wen, Y., Ma, L., & Ju, C.
- Affiliations
- Department of Anesthesiology, Critical Care and Pain Medicine, University of Texas McGovern Medical School, Houston, Texas, USA
- National Cancer Institute (US)
- Corresponding author
- Ju, Cynthia
- Venue
- eGastroenterology
- Publisher
- BMJ
- Published
- 2023-10
- Volume
- 1
- Issue
- 2
- Pages
- e100020
- ISSN
- 2766-0125 (ISSN-L)
- 2976-7296
- PMC
- PMC10704956
- OpenAlex
- W4387784557
- Cited by
- 31
- References
- 137
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 3 · 2023: 1
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- eGastroenterology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Center for Cancer Research, National Cancer Institute (ZIA BC 012079, ZIA BC 012083)
- National Institutes of Health (DK121330, DK122708, DK122796)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- chronic liver disease, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, liver cancer, pathogenesis, therapeutic target, non-coding RNA, autophagy, macrophages, single-cell RNA sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases. https://app.cochat.ai/papers/10.1136/egastro-2023-100020
- The paper
- Wen, Y., Ma, L., & Ju, C. (2023). Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases. eGastroenterology. https://doi.org/10.1136/egastro-2023-100020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.